The latest price target for ATAI Life Sciences (NASDAQ:ATAI) was reported by HC Wainwright & Co. on August 30, 2024. The analyst firm set a price target for $15.00 expecting ATAI to rise to within 12 months (a possible 837.50% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for ATAI Life Sciences (NASDAQ:ATAI) was provided by HC Wainwright & Co., and ATAI Life Sciences reiterated their buy rating.

The last upgrade for ATAI Life Sciences NV happened on April 3, 2024 when Maxim Group raised their price target to $6. Maxim Group previously had a hold for ATAI Life Sciences NV.

There is no last downgrade for ATAI Life Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ATAI Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ATAI Life Sciences was filed on August 30, 2024 so you should expect the next rating to be made available sometime around August 30, 2025.

While ratings are subjective and will change, the latest ATAI Life Sciences (ATAI) rating was a reiterated with a price target of $15.00 to $15.00. The current price ATAI Life Sciences (ATAI) is trading at is $1.60, which is out of the analyst’s predicted range.